Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOJ0V6)

Drug Name
Metoprolol Drug Info
Synonyms
Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
Therapeutic ClassAntihypertensive Agents
Cross-matching ID
PubChem CID
4171
ChEBI ID
CHEMBL13
CAS Number
CAS 51384-51-1
TTD Drug ID
D0I2MK
VARIDT Drug ID
DR00436
INTEDE Drug ID
DR1071
ACDINA Drug ID
D00424

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Legionellosis -1.69 4.70e-2 51/57 (89.47%) SAR1A;IL6;HSPD1;...
NF-kappa B signaling pathway -1.70 4.97e-2 90/104 (86.54%) IL1B;EDA2R;LBP;...
Neutrophil extracellular trap formation -1.75 2.65e-2 101/189 (53.44%) SRC;NFKB1;RAC2;...
Ferroptosis -1.78 1.74e-2 36/41 (87.8%) TFRC;ACSL5;PCBP2;...
NOD-like receptor signaling pathway -1.83 8.52e-3 145/181 (80.11%) IRAK4;MAP3K7;IKBKB;...
Complement and coagulation cascades -1.83 9.94e-3 76/85 (89.41%) C1QA;CFHR2;F8;...
Transcriptional misregulation in cancer -1.86 5.97e-3 158/192 (82.29%) MLLT3;NFKB1;SPINT1;...
Sulfur metabolism -1.89 4.97e-3 9/10 (90%) MPST;TST;SQOR;...
Rheumatoid arthritis -1.96 6.63e-3 78/93 (83.87%) CD86;IL15;TNFRSF11A;...
IL-17 signaling pathway -2.05 0.00e+0 84/94 (89.36%) MAPK11;TAB2;MAPK3;...
Mineral absorption -2.09 0.00e+0 48/60 (80%) ATP1A2;TF;SLC34A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12.5uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H